{"transactions":[{"id":1423157,"issuer":{"id":87994,"kind":"organization","name":"AGILE THERAPEUTICS INC","symbol":"AGRX"},"owners":[{"id":87997,"kind":"person","name":"Korner Paul","position":1,"cik":"0001663000","reported_name":"Korner Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-08-26T17:40:47.000Z","date":"2024-08-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3375,"price":1.52,"value":5130.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Upon the consummation of the Merger, pursuant to the Merger Agreement, 3,375 shares of Common Stock were converted into the right to receive the Merger Consideration, for an aggregate of $5,130, equal to the product of (x) the Merger Consideration, multiplied by (y) the total number of shares of Common Stock owned by the reporting person."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-24-092944","document":"tm2422466-8_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1261249/000110465924092944/tm2422466-8_4seq1.xml","form_type":"4"}},{"id":1423156,"issuer":{"id":87994,"kind":"organization","name":"AGILE THERAPEUTICS INC","symbol":"AGRX"},"owners":[{"id":87997,"kind":"person","name":"Korner Paul","position":1,"cik":"0001663000","reported_name":"Korner Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-08-26T17:40:47.000Z","date":"2024-08-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10125,"price":1.52,"value":15390.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Upon the consummation of the merger (the \"Merger\") pursuant to that certain Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of June 25, 2024, by and among Agile Therapeutics, Inc. (the \"Company\"), Insud Pharma, S.L. (\"Insud\"), and Exeltis Project, Inc., a Delaware corporation and indirect, wholly owned subsidiary of Insud (\"Merger Sub\"), 10,125 restricted stock units (\"Agile RSUs\") were cancelled and converted into the right to receive a cash payment of $1.52 (the \"Merger Consideration\") per Agile RSU, for an aggregate of $15,390, equal to the product of (x) the Merger Consideration, multiplied by (y) the total number of shares of Common Stock subject to such Agile RSU owned by the reporting person."}],"balance_after":3375,"source":{"system":"sec-edgar","filing":"0001104659-24-092944","document":"tm2422466-8_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1261249/000110465924092944/tm2422466-8_4seq1.xml","form_type":"4"}},{"id":1840945,"issuer":{"id":87994,"kind":"organization","name":"AGILE THERAPEUTICS INC","symbol":"AGRX"},"owners":[{"id":87997,"kind":"person","name":"Korner Paul","position":1,"cik":"0001663000","reported_name":"Korner Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2023-06-30T16:38:06.000Z","date":"2023-06-28","kind":"grant","planned":false,"acquired":true,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on June 28, 2023. 25% of the shares subject to the stock option vest on June 28, 2024, and the remaining shares vest in 36 substantially equal monthly installments over the following three years such that the option will be fully vested on June 28, 2027."}],"balance_after":4500,"derivative":{"exercise_price":2.48,"expiration_date":"2033-06-27","underlying":"Common Stock","underlying_shares":4500},"source":{"system":"sec-edgar","filing":"0001104659-23-077177","document":"tm2320328-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1261249/000110465923077177/tm2320328-4_4seq1.xml","form_type":"4"}},{"id":1840944,"issuer":{"id":87994,"kind":"organization","name":"AGILE THERAPEUTICS INC","symbol":"AGRX"},"owners":[{"id":87997,"kind":"person","name":"Korner Paul","position":1,"cik":"0001663000","reported_name":"Korner Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-06-30T16:38:06.000Z","date":"2023-06-28","kind":"grant","planned":false,"acquired":true,"shares":13500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\") which were granted on June 28, 2023. The RSUs will vest in four equal installments over four years upon the anniversary of the grant, such that the RSUs will be fully vested on June 28, 2027."}],"balance_after":13500,"source":{"system":"sec-edgar","filing":"0001104659-23-077177","document":"tm2320328-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1261249/000110465923077177/tm2320328-4_4seq1.xml","form_type":"4"}},{"id":2117680,"issuer":{"id":87994,"kind":"organization","name":"AGILE THERAPEUTICS INC","symbol":"AGRX"},"owners":[{"id":87997,"kind":"person","name":"Korner Paul","position":1,"cik":"0001663000","reported_name":"Korner Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP and CMO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-11-14T16:35:40.000Z","date":"2022-11-09","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on November 9, 2022. 25% of the shares subject to the stock option vest on November 9, 2023, and the remaining shares vest in 36 substantially equal monthly installments over the following three years such that the option will be fully vested on November 9, 2026."}],"balance_after":10000,"derivative":{"exercise_price":0.2,"expiration_date":"2032-11-08","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001104659-22-118639","document":"tm2230300-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1261249/000110465922118639/tm2230300-4_4seq1.xml","form_type":"4"}},{"id":2430198,"issuer":{"id":87994,"kind":"organization","name":"AGILE THERAPEUTICS INC","symbol":"AGRX"},"owners":[{"id":87997,"kind":"person","name":"Korner Paul","position":1,"cik":"0001663000","reported_name":"Korner Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP and CMO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-01-20T21:31:29.000Z","date":"2022-01-19","kind":"grant","acquired":true,"shares":225000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on January 19, 2022. 25% of the shares subject to the stock option vest on January 19, 2023, and the remaining shares vest in 36 substantially\nequal monthly installments over the following three years such that the option will be fully vested on January 19, 2026."}],"balance_after":225000,"derivative":{"exercise_price":0.342,"expiration_date":"2032-01-18","underlying":"Common Stock","underlying_shares":225000},"source":{"system":"sec-edgar","filing":"0001104659-22-006129","document":"tm224102-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1261249/000110465922006129/tm224102-2_4seq1.xml","form_type":"4"}},{"id":2891989,"issuer":{"id":87994,"kind":"organization","name":"AGILE THERAPEUTICS INC","symbol":"AGRX"},"owners":[{"id":87997,"kind":"person","name":"Korner Paul","position":1,"cik":"0001663000","reported_name":"Korner Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP and CMO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-01-28T18:32:17.000Z","date":"2021-01-27","kind":"grant","acquired":true,"shares":173160,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on January 27, 2021. 25% of the shares subject to the stock option vest on January 27, 2022, and the remaining shares vest in 36 substantially equal monthly installments over the following three years such that the option will be fully vested on January 27, 2025."}],"balance_after":173160,"derivative":{"exercise_price":2.82,"expiration_date":"2031-01-26","underlying":"Common Stock","underlying_shares":173160},"source":{"system":"sec-edgar","filing":"0001104659-21-008898","document":"tm214338-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1261249/000110465921008898/tm214338-6_4seq1.xml","form_type":"4"}},{"id":3055641,"issuer":{"id":87994,"kind":"organization","name":"AGILE THERAPEUTICS INC","symbol":"AGRX"},"owners":[{"id":87997,"kind":"person","name":"Korner Paul","position":1,"cik":"0001663000","reported_name":"Korner Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Medical Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-08-17T18:47:29.000Z","date":"2020-08-17","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on August 17, 2020. 25% of the shares subject to the stock option vest on August 17, 2021, and the remaining shares vest in 36 substantially equal monthly installments over the following three years such that the option will be fully vested on August 17, 2024."}],"balance_after":150000,"derivative":{"exercise_price":2.87,"expiration_date":"2030-08-16","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001104659-20-096165","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1261249/000110465920096165/a4.xml","form_type":"4"}},{"id":4484096,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":87997,"kind":"person","name":"Korner Paul","position":1,"cik":"0001663000","reported_name":"Korner Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-01-24T01:49:10.000Z","date":"2017-01-19","kind":"grant","acquired":true,"shares":74233,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 19, 2017, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date."}],"balance_after":74233,"derivative":{"exercise_price":13.9,"expiration_date":"2027-01-19","underlying":"Common Stock","underlying_shares":74233},"source":{"system":"sec-edgar","filing":"0001140361-17-002600","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000114036117002600/doc1.xml","form_type":"4"}},{"id":4484095,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":87997,"kind":"person","name":"Korner Paul","position":1,"cik":"0001663000","reported_name":"Korner Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2017-01-24T01:49:10.000Z","date":"2017-01-19","kind":"grant","acquired":true,"shares":17985,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock units (\"RSUs\").  The Reporting Person is entitled to receive one (1) shares of Common Stock for each one (1) RSU upon the vesting thereof."}],"balance_after":72608,"source":{"system":"sec-edgar","filing":"0001140361-17-002600","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000114036117002600/doc1.xml","form_type":"4"}},{"id":4484153,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":87997,"kind":"person","name":"Korner Paul","position":1,"cik":"0001663000","reported_name":"Korner Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2017-01-24T01:48:33.000Z","date":"2017-01-05","kind":"sale","acquired":false,"shares":6130,"price":12.95,"value":79383.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were automatically sold pursuant to the Issuer's 2014 Equity Incentive Award Plan to cover tax liability upon the vesting of outstanding Restricted Stock Units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 45,565 RSUs.  The reporting person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof."}],"balance_after":54623,"source":{"system":"sec-edgar","filing":"0001140361-17-002599","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000114036117002599/doc1.xml","form_type":"4"}}]}